Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Urinary Tract Infection (cUTI)

Next Previous
X
Search
Trial Profile

A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Urinary Tract Infection (cUTI)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cilastatin/imipenem/relebactam (Primary) ; Ciprofloxacin; Imipenem/cilastatin
  • Indications Bacterial infections; Pyelonephritis; Urinary tract infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck Sharp & Dohme

    • Most Recent Events

    • 20 Jun 2016 Primary endpoint has been met. (Proportion of participants with a favorable microbiological response at completion of IV study therapy), as reported in a Merck media release.
    • 20 Jun 2016 Results published in a Merck media release.
    • 15 Jun 2016 Data will be presented at the American Society for Microbiology's ASM Microbe 2016 meeting, according to a Merck & Co. media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top